

Corrigendum to "Efficacy of evocalcet in previously cinacalcet-treated secondary hyperparathyroidism patients," [*Kidney Int. Rep.* 2021; <https://doi.org/10.1016/j.ekir.2021.08.020>]



Kidney Int Rep (2021) 6, 2936–2937; <https://doi.org/10.1016/j.ekir.2021.09.011> © 2021 International Society of Nephrology. Published by Elsevier Inc.

Fumihiko Koiwa¹, Shin Tokunaga^{2,3}, Shinji Asada², Yuichi Endo³, Masafumi Fukagawa⁴ and Tadao Akizawa⁵

¹Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan; ²Medical Affairs Department, Kyowa Kirin Co., Ltd., Tokyo, Japan; ³R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan; ⁴Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan; and ⁵Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

The authors regret that the published version of the above article contained two errors. The corrected content is detailed below.

Figure 1 is corrected to the following version:




Figure 1. Trends in the (a) median (interquartile range) serum intact PTH levels, (b) mean (SD) serum corrected calcium, and (c) serum phosphate levels throughout the study period (week 0 to week 30) in cinacalcet nonusers and users. Yellow-shaded area indicates a guideline target range. PTH, parathyroid hormone.

The second paragraph of the Discussion section is corrected to the following version:

In the previous phase III head-to-head comparison study, the proportion of patients who achieved the target levels of intact PTH but not weekly trends in the intact PTH, whole PTH, corrected calcium, serum-ionized calcium, phosphorus, and intact FGF23 levels, was statistically analyzed between the evocalcet and cinacalcet groups because of differences in the baseline characteristics and in the dose adjustment patterns for cinacalcet and evocalcet.

The authors would like to apologise for any inconvenience caused.

Correspondence: Fumihiko Koiwa, Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama 227-8501, Japan. E-mail: koiwa-f@med.showa-u.ac.jp
